急性髓系白血病(AML)院内感染的相关因素分析
Analysis of Related Factors of Nosocomial Infection in Patients with Acute Myeloid Leukemia
DOI: 10.12677/ACM.2021.118510, PDF,   
作者: 许丽琴, 贾振丽, 王 震:青岛市黄岛区人民医院血液科,山东 青岛
关键词: 急性髓系白血病感染凝血指标早期预防Acute Myeloid Leukemia Infected Coagulation Index Early Prevention
摘要: 目的:探究急性髓系白血病(Acute myelogenous leukemia, AML)院内感染的相关因素,及时给予早期诊断和早期治疗。方法:回顾性分析自2011年1月至2020年1月收治我院血液科的131例患者,根据是否存在院内感染进行分组,即感染组和非感染组。感染组AML患者64例,包括30例男性,34例女性;非感染组AML患者67例,包括32例男性,35例女性。统计并记录患者的一般基准资料,凝血指标,利用单因素分析和Logistic回归性分析,多因素分析,评估相关因素。结果:结果显示,WBC,APTT,PT,D-D,FIB和血红蛋白是影响AML患者院内感染的相关因素(P < 0.05)。相关因素赋值如下:WBC < 2.0 × 109/L为1,WBC ≥ 2.0 × 109/L为2;APTT < 33 s为1,APTT ≥ 33 s为2;PT < 10 s为1,PT ≥ 10 s为2;D-D < 0.2 ng/L为1,D-D ≥ 0.2 ng/L为2;FIB < 4 g/L为1,FIB ≥ 4 g/L为2;血红蛋白 < 60 g/L为1,血红蛋白 ≥ 60 g/L为2。多因素分析结果显示,WBC ≥ 2.0 × 109/L,APTT ≥ 33 s,PT ≥ 10 s,D-D ≥ 0.2 ng/L,FIB ≥ 4 g/L和血红蛋白 < 60 g/L是影响AML患者院内感染的危险因素。结论:WBC ≥ 2.0 × 109/L,APTT ≥ 33 s,PT ≥ 10 s,D-D ≥ 0.2 ng/L,FIB ≥ 4 g/L和血红蛋白 < 60 g/L是影响AML患者院内感染的危险因素,应及时给予早期诊断和早期治疗。
Abstract: Objective: To explore the related factors of nosocomial infection in acute myelogenous leukemia (AML), and to give early diagnosis and treatment. Methods: From January 2011 to January 2020, 131 patients in the Department of Hematology of our hospital were retrospectively analyzed. They were divided into infection group and non infection group according to whether there was nosocomial infection. In the infection group, there were 64 AML patients, including 30 males and 34 females. There were 67 AML patients in non infection group, including 32 males and 35 females. The general baseline data and coagulation indexes of the patients were recorded. Univariate analysis, logistic regression analysis and multivariate analysis were used to evaluate the related factors. Results: The results showed that WBC, APTT, PT, D-D, FIB and hemoglobin were the related factors of nosocomial infection in AML patients (P < 0.05). The related factors were assigned as follows: WBC < 2.0 × 109 / L is 1, WBC ≥ 2.0 × 109/L is 2; APTT < 33 s is 1, APTT ≥ 33 s is 2; PT < 10 s is 1, PT ≥ 10 s is 2; D-D < 2 ng/L is 1, D-D ≥ 0.2 ng/L is 2; FIB < 4 g/L is 1, FIB ≥ 4 g/L is 2; hemoglobin < 60 g/L is 1, hemoglobin ≥ 60 g/L is 2. The results of multivariate analysis showed that WBC ≥ 2.0 × 109/L, APTT ≥ 33 s, PT ≥ 10 s, D-D ≥ 0.2 ng/L, FIB ≥ 4 g/L and hemoglobin < 60 g/L were risk factors for nosocomial infection in AML patients. Conclusion: WBC ≥ 2.0 × 109/L, APTT ≥ 33 s, PT ≥ 10 s, D-D ≥ 0.2 ng/L, FIB ≥ 4 g/L and hemoglobin < 60 g/L are the risk factors of nosocomial infection in AML patients. Early diagnosis and treatment should be given in time.
文章引用:许丽琴, 贾振丽, 王震. 急性髓系白血病(AML)院内感染的相关因素分析[J]. 临床医学进展, 2021, 11(8): 3498-3503. https://doi.org/10.12677/ACM.2021.118510

参考文献

[1] DiNardo, C.D., Maiti, A., Rausch, C.R., et al. (2020) 10-Day Decitabine with Venetoclax for Newly Diagnosed Intensive Chemotherapy Ineligible, and Relapsed or Refractory Acute Myeloid Leukaemia: A Single-Centre, Phase 2 Trial. The Lancet Haematology, 7, 724-736. [Google Scholar] [CrossRef
[2] Platzbecker, U., Middeke, J.M., Sockel, K., et al. (2018) Measurable Residual Disease-Guided Treatment with Azacitidine to Prevent Haematological Relapse in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukaemia (RELAZA2): An Open-Label, Multicentre, Phase 2 Trial. The Lancet Oncology, 19, 1668-1679. [Google Scholar] [CrossRef
[3] Anguille, S., Van de Velde, A.L., Smits, E.L., et al. (2017) Dendritic Cell Vaccination as Postremission Treatment to Prevent or Delay Relapse in Acute Myeloid Leukemia. Blood, 130, 1713-1721. [Google Scholar] [CrossRef] [PubMed]
[4] 姜巧丽, 樊浩然, 赵东亮. 急性髓系白血病化疗患者凝血功能与其感染关系及相关因素分析[J]. 四川解剖学杂志, 2020, 28(3): 161-162.
[5] 陈晓敏, 唐柳, 刘洋, 等. 成人急性淋巴细胞白血病患者化疗期间院内感染的病原菌分布和耐药情况, 危险因素分析[J]. 山东医药, 2020, 1164(6): 63-66.
[6] 崔清彦, 张婷, 陈森. 儿童急性淋巴细胞白血病化疗后感染的临床特征及危险因素分析[J]. 中国现代医学杂志, 2020, 30(23): 78-82.
[7] Sung, L., Aplenc, R., Alonzo, T.A., et al. (2016) Association between Prolonged Neutropenia and Reduced Relapse Risk in Pediatric AML: A Report from the Children’s Oncology Group. International Journal of Cancer, 139, 1930-1935. [Google Scholar] [CrossRef] [PubMed]
[8] Ballo, O., Kreisel, E.M., Eladly, F., et al. (2020) Use of Carbapenems and Glycopeptides Increases Risk for Clostridioides Difficile Infections in Acute Myeloid Leukemia Patients Undergoing Intensive Induction Chemotherapy. Annals of Hematology, 99, 2547-2553. [Google Scholar] [CrossRef] [PubMed]
[9] Demichelis-Gómez, R., Zapata-Canto, N., Leyto-Cruz, F., et al. (2020) Acute Myeloid Leukemia in Mexico: The Specific Challenges of a Developing Country. Results from a Multicenter National Registry. Clinical Lymphoma, Myeloma & Leukemia, 20, 295-303. [Google Scholar] [CrossRef] [PubMed]
[10] Rodríguez-Veiga, R., Montesinos, P., Boluda, B., et al. (2019) Incidence and Outcome of Invasive Fungal Disease after Front-Line Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Impact of Antifungal Prophylaxis. Annals of Hematology, 98, 2081-2088. [Google Scholar] [CrossRef] [PubMed]
[11] 肖喜春, 司金春, 陈淑霞, 等. 老年急性髓系白血病患者化疗期间医院感染的危险因素及防治[J]. 中华实验和临床感染病杂志(电子版), 2014(5): 631-634.
[12] 朱齐兵, 陈慧君, 唐小万, 等. 急性白血病患者化疗后血流感染病原菌分布及危险因素分析[J]. 中国医药, 2018(1): 104-107.